I use research + strategy to meaningfully enhance people’s lives.

2022-25: At Vanguard, I spearheaded a multi-year research program launching STAR, a web and mobile tool for tracking money movement, resulting in $285M additional annual assets under management and $1.4M in annual operational savings.

2021: ClinicalPath is Elsevier’s industry-leading clinical decision support for oncologists. In 2021, Elsevier wanted to take a fresh look at ClinicalPath and position it for commercial success in a rapidly changing landscape.

2022: At EPAM, I supported a Fortune 50 client seeking to offer consumers an omni-channel experience to help manage common, chronic conditions. In 2022 I led research to identify opportunities to drive consumer engagement and improve diabetes and colorectal cancer outcomes.

2015: Diabetic retinopathy (DR) is the most common cause of vision loss among working-age adults. 90% of cases can be prevented with early treatment, but many patients do not complete the necessary screening. Eyes on Site is a low-barrier, mobile screening service which leverages advanced imaging to detect and treat DR early.

2019: Philadelphia has the highest rate of opioid overdose death of any major city. What began as an effort to incorporate evidence-based substance use treatment in Penn Medicine’s emergency departments is now a transformative model for caring for patients with opioid use disorder.

2018: Home care is a valuable tool to keep sick patients comfortable and out of the hospital. However, traditional home care fails to meet the needs of patients with advanced heart failure. An interdisciplinary team developed a novel home care service specialized for heart failure patients.